Breaking News

AZ To Buy Ardea

Gout candidate leads $1.3 billion buyout

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AstraZeneca will acquire Ardea Biosciences for approximately $1.26 billion. Ardea is focused on small-molecule therapeutics; its most advanced product candidate, lesinurad, is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout. Lesinurad is a selective inhibitor of URAT1, a transporter in the proximal tubule cells of the kidney that regulates uric acid excretion from the body, which is being developed as an oral, once-d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters